EASL 2015 HCV Abstract Choices: Dr. Lebovics

Posted on April 16, 2015

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book.

Current agents in special populations

Abstract G02
Ledipasvir/Sofosbuvir with Ribavirin is Safe And Efficacious in Decompensated and Post Liver Transplantation Patients with HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial

Manns M, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O005
Retreatment of Patients who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens with Ledipasvir/Sofosbuvir for 24 Weeks

Lawitz E, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O007
All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Interim Report From the HCV-TARGET Real World Experience

Reddy R, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O109
Treatment of Severe HCV-Recurrence After Liver Transplantation Using Sofosbuvir-Based Regimens: the ANRS C023 CUPILT Study

Dumortier J, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O110
Simeprevir + Sofosbuvir Combination Therapy For Recurrent Genotype-1 Hepatitis C in Liver Transplant Recipients: a Real-Life Multicenter Experience

Te H, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LO1
Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir For Treating HCV GT1 Infection in Patients with Severe Renal Impairment or End-Stage Renal Disease: The RUBY-I Study

Pockros PJ, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Agents pending approval in US

Abstract O001
C-SALVAGE: Grazoprevir (GZR; MK-5172), Elbasvir (EBR; MK-8742) and Ribavirin (RBV) For Chronic HCV-Genotype 1 (GT1) Infection After Failure of Direct-Acting Antiviral (DAA) Therapy

Forns X, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O006
C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection, For Durations of 4, 6 or 8 Weeks and Genotype 3 Infection For Durations of 8 or 12 Weeks

Poordad F, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O008
Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child–Pugh Class B Cirrhosis (C-SALT Part A)

Jacobson IM, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract G15
The Association of Sofosbuvir and Daclatasvir For Treating Severe Recurrence of HCV Infection After Liver Transplantation: Results From a Large French Prospective Multicentric ANRS CO23 CUPILT Cohort

Coilly A, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LO3
Safety and Efficacy of the Combination Daclatasvir–Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER

Pol S, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LO8
Daclatasvir, Sofosbuvir, and Ribavirin Combination For HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study

Poordad F, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Chronic Hepatitis C Assessment, Follow-up

Abstract O003
Can Hepatitis C Treatment Be Safely Delayed? Evidence From the Veterans Administration Healthcare System

McCombs JS, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O023
Repeated Measurement of Non-Invasive Fibrosis Markers to Assess Hepatitis C Progression and Clinical Outcomes

Lens S, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O058
Increased Cancer Rates in Patients With Chronic Hepatitis C: an Analysis of the Cancer Registry in a Large U.S. Health Maintenance Organization

Nyberg AH, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O061
Incidence of Hepatitis C Reinfection Following Sustained Virological Response – A Seven Year Follow-Up of Scandinavian Patients Infected Through Injecting Drug Use

Midgard H, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O063
HCV Reinfection Cases in Phase 3 Studies of Sofosbuvir

Svarovskaia E, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract O120
Advanced Fibrosis is Common in Individuals Whose Hepatitis C Has Not Been Diagnosed: Results From the National Health and Nutrition Examination Survey 2001–2012

Udompap P, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.


No Replies to "EASL 2015 HCV Abstract Choices: Dr. Lebovics"


    Join the discussion

    Some html is OK